Compare TCI & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCI | IMMP |
|---|---|---|
| Founded | 1983 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.3M | 426.9M |
| IPO Year | N/A | N/A |
| Metric | TCI | IMMP |
|---|---|---|
| Price | $53.75 | $2.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.7K | ★ 174.9K |
| Earning Date | 03-19-2026 | 02-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.87 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $48,675,000.00 | $3,306,742.00 |
| Revenue This Year | N/A | $292.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $82.69 | ★ N/A |
| Revenue Growth | N/A | ★ 31.28 |
| 52 Week Low | $26.02 | $1.32 |
| 52 Week High | $59.65 | $3.53 |
| Indicator | TCI | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 49.00 |
| Support Level | $53.57 | $2.56 |
| Resistance Level | $54.56 | $2.83 |
| Average True Range (ATR) | 0.82 | 0.15 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 48.17 | 39.81 |
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.